Posted by Mark Nessim
By Mark Nessim · Reviewed by Dr. Mark, Physician & Formulator
Three weeks ago, on July 24, 2026, an FDA advisory committee did something unusual: it voted 8–6 to recommend that BPC-157 — a peptide with enormous social-media hype and almost no published human trial data — be added to the list of substances pharmacies are allowed to compound. It did so over the objections of the FDA's own scientific reviewers, who had concluded the safety and efficacy data didn't support it.
If you spend any time in fitness, recovery, or GLP-1 communities, you've heard of BPC-157. It's promoted for tendon healing, gut repair, injury recovery, and — increasingly — as part of the peptide conversation around weight loss. So it's worth doing what the marketing rarely does: separating what's actually been demonstrated from what's been extrapolated.
What BPC-157 is
BPC-157 (Body Protection Compound-157) is a synthetic fragment of a protein found in human gastric juice. The name is not a brand flourish — it comes from the research literature, where the parent protein was studied for its role in protecting the stomach lining. The synthetic fragment has been studied in animals for decades, mostly by a small number of research groups, for wound healing, tendon-to-bone healing, gut injury, and more.
What the evidence actually shows
The animal literature is genuinely large — over a hundred studies in rodents showing effects on tendon, ligament, muscle, and gut tissue healing. If you've seen impressive-sounding claims, they almost all trace back to this animal work.
The human literature is a different story. As of March 2026, only three published human studies exist — all small pilot studies. The most cited is a Phase 2 trial in ulcerative colitis reporting dose-dependent symptom improvement, at pilot scale. The largest human trial conducted, with 42 volunteers, never published its results. There are no completed Phase 1, 2, or 3 trials under an FDA-sanctioned Investigational New Drug application.
That's the honest summary: extensive animal data, nearly no human data. Animal results in regenerative medicine frequently fail to translate to humans — which is exactly why human trials exist. BPC-157 isn't proven ineffective. It's unproven, which is a different thing, and the distinction matters when the substance is being injected.
What the FDA vote does — and doesn't — change
BPC-157 currently sits on the FDA's Category 2 list, meaning it cannot legally be compounded or dispensed by U.S. pharmacies. The FDA placed it there in 2023, citing insufficient clinical safety and efficacy data.
The July 2026 committee vote recommends moving it — along with five other peptides including TB-500, MOTS-c, Epitalon, KPV, and Semax — to the list that would allow licensed pharmacies to compound it. But a recommendation is not a rule. The FDA must now run formal rulemaking: a proposed rule, a public comment period, a final determination. On an optimistic timeline, legally compounded BPC-157 would not be available from a licensed pharmacy before late 2027.
Which means everything sold today as BPC-157 — the vials, the “research use only” listings, the products in supplement-adjacent packaging — exists outside pharmaceutical quality control. No sterility standards, no dosing verification, no legal manufacturer accountable for what's actually in the vial. That's not a moral judgment about the people buying it. It is simply the current state of the supply.
Where this leaves someone on a GLP-1
The reason BPC-157 keeps surfacing in GLP-1 communities is understandable: people losing weight quickly are thinking hard about tissue, recovery, and preserving what they've built. Those are the right concerns. The question is whether an unproven injectable is the right tool for them, when the interventions with actual human evidence are sitting in plain sight.
Daily protein intake sufficient to protect lean mass during rapid weight loss is the least glamorous and best-established lever there is. Creatine monohydrate carries three decades of human trials — pooled analyses across hundreds of studies show no greater adverse-event rate than placebo — with its strongest evidence in muscle and a growing literature on cognition. Neither will ever trend on social media, because you can buy both at a grocery store. That is, in its way, the point.
If you're navigating muscle preservation on a GLP-1 medication specifically, we've written a practical guide: how to prevent muscle loss on Ozempic and Wegovy. And if hitting a real protein number is the sticking point, that's the problem ASP-1 was formulated to solve — one scoop, with creatine already in it.
The bottom line
BPC-157 is interesting biology with a genuinely thin human evidence base, a supply chain currently outside any quality regulation, and a regulatory process that — even after July's vote — won't change that before late 2027 at the earliest. Watching the trials is reasonable. Treating the animal literature as settled human science is not.
We'll keep covering the evidence as it develops — including when it cuts against the convenient conclusion.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
